Veradigm Announces the Resignation of Board Director Beth Altman Due to Health Reasons

$MDRX
EDP Services
Technology
Get the next $MDRX alert in real time by email

Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that on January 28, 2025, Beth Altman stepped down from the Company's Board of Directors ("Board") due to health reasons. Her decision to resign was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Ms. Altman's resignation has no impact on the Company's ongoing restatement of its 2022 financial statements.

Altman has been a valued advisor since 2020 and, as Audit Committee Chair, has been instrumental in helping the Company navigate a challenging period. Following Altman's resignation, the Board appointed Greg Garrison to the Audit Committee of the Board and as interim Chair of the Audit Committee. Garrison previously served as the Chair of the Audit Committee from May 2016 through June 2022.

"On behalf of the entire Board, I thank Beth for the insight, dedication, and expertise that she brought to Veradigm," said Greg Garrison, Chairman of the Board. "We are grateful for her valuable contributions and wish her all the best."

Stockholder Input Welcomed on Board Refreshment

The Board is seeking input from stockholders in identifying highly qualified individuals with significant relevant experience to serve on the Board. Stockholders interested in submitting potential candidates should contact Jenny Gelinas, whose contact information is below.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

Investors:

Jenny Gelinas

312-506-1237

jenny.gelinas@veradigm.com

Media:

Concetta Rasiarmos

630-740-3152

concetta.rasiarmos@veradigm.com

Get the next $MDRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MDRX

DatePrice TargetRatingAnalyst
3/19/2024$15.00 → $10.00Buy → Hold
Deutsche Bank
1/3/2024$11.00Equal Weight
Barclays
7/6/2023Buy → Hold
Argus
4/12/2023$13.00Equal-Weight
Stephens
2/1/2023$17.00 → $18.50Overweight → Neutral
Piper Sandler
12/7/2022$26.00Hold → Buy
Argus
11/9/2022$22.00 → $23.00Neutral → Buy
Goldman
11/4/2022$17.00Overweight
Piper Sandler
More analyst ratings

$MDRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Veradigm Amends and Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire on February 26, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to August 20, 2025. To reflect changes in the price of Company common stock since February 26, 2024, the amendment to the Rights Plan also updates the exercise price for the purchase of rights under the Rights Plan from $50.00 to $32.00. The

    $MDRX
    EDP Services
    Technology
  • Veradigm Introduces Cardiometabolic Clinical Registry Datasets to Enhance the Next Generation of Real-World Research

    With the introduction of seven new disease-specific registry datasets, Veradigm is enabling deep, targeted research to drive innovation and enhance real-world clinical insights Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today the launch of its disease-specific cardiometabolic Clinical Data Registry datasets, which contain de-identified information about patients' health and care for a specific condition or disease. These datasets provide researchers with access to specialty, Natural Language Processing (NLP)-enhanced real-world data to advance the understanding of patient insights and clinical details to support research throughout the d

    $MDRX
    EDP Services
    Technology

$MDRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MDRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MDRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MDRX
SEC Filings

See more

$MDRX
Leadership Updates

Live Leadership Updates

See more
  • Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Sprinklr Set to Join S&P SmallCap 600

    NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea

    $CXM
    $MDRX
    $SPGI
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Finance: Consumer Services
  • Omnicell Elects Eileen Voynick to Board of Directors

    Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

    $MDRX
    $OMCL
    $CDK
    EDP Services
    Technology
    Computer Manufacturing
    Retail: Computer Software & Peripheral Equipment

$MDRX
Financials

Live finance-specific insights

See more
  • Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review

    Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti

    $MDRX
    EDP Services
    Technology
  • Veradigm to Release Fourth Quarter and Fiscal Year 2022 Financial Results March 1

    Veradigm®, Inc. (NASDAQ:MDRX), will report its financial results for the three and twelve months ended December 31, 2022 after the close of the regular stock market hours on Wednesday, March 1, 2023. Veradigm management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Fourth-Quarter 2022 Financial Results Call Details To listen to the conference call, participants may log onto the Veradigm Investor Relations website. Participants also may access the conference call by dialing 877-269-7756 or 201-689-7817 and requesting Conference ID # 13735356. A replay of the call will be available for a period of a year on the Veradi

    $MDRX
    EDP Services
    Technology
  • Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023

    Veradigm Inc. (NASDAQ:MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm repurchased $57 million of its common stock, bringing its full year total to $234 million. The company also introduced initial financial guidance for Fiscal 2023 as follows: Revenue is expected between $640 million and $660

    $MDRX
    EDP Services
    Technology

$MDRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more